-
Puromycin aminonucleoside: A Mechanism-First Guide
2026-09-02
Puromycin aminonucleoside is more than a nephrotoxin: it is a controllable perturbation for connecting podocyte structure, filtration-barrier failure, and renal pathology. This mechanism-first guide shows how to design orthogonal assays, interpret transport-dependent cytotoxicity, and avoid overstating an experimental FSGS model.
-
Cx43/NF-κB Drives AngII-Induced M1 Polarization
2026-09-02
The reference study shows that angiotensin II drives RAW264.7 macrophages toward a pro-inflammatory M1 phenotype through a connexin 43 (Cx43)/NF-κB signaling axis. Its combined inhibitor, cytokine, transcriptional, and phenotyping experiments position Cx43 as a mechanistically relevant regulator of macrophage inflammation, while also highlighting the need to distinguish Cx43 channel functions in follow-up studies.
-
PPARγ Activation and Macrophage Polarization in IBD
2026-09-01
This study links PPARγ activation with a shift from pro-inflammatory M1 toward reparative M2 macrophage features in DSS-induced experimental colitis. By combining RAW264.7-cell experiments with a mouse model, it identifies coordinated STAT-1 suppression and STAT-6 activation as a mechanistic pathway associated with improved disease signs, mucosal structure, and barrier-protein expression.
-
Fingolimod: A Trafficking-Control Assay Framework
2026-09-01
Fingolimod (FTY720) is examined here as a mechanistic trafficking perturbation tool rather than simply an MS drug. This assay-centered framework explains how to separate lymphocyte egress inhibition, CNS signaling, cytotoxicity, and emerging magnetic T-cell engineering hypotheses.
-
DMXAA (Vadimezan): From Vessel Collapse to STING
2026-08-31
A mechanism-first guide to using DMXAA (Vadimezan) in translational cancer research, connecting tumor vascular disruption and VEGFR2 signaling with emerging delivery strategies for innate immune activation.
-
Canagliflozin Remodels Mitochondria in Diabetic Kidneys
2026-08-31
This 2025 study shows that canagliflozin improves mitochondrial architecture and bioenergetics in proximal tubular cells from hypertensive–diabetic mice, with stronger functional effects in males than females. The findings extend the interpretation of SGLT2 inhibition beyond glucose lowering and identify mitochondrial remodeling as a plausible component of kidney protection.
-
Forsythoside E Workflow for PKM2 Immunometabolism
2026-08-30
Forsythoside E is a mechanism-oriented tool for connecting PKM2 regulation with macrophage metabolism, STAT3 signaling, and inflammatory injury. This workflow shows how to test its effects from RAW264.7 assays through sepsis-induced liver injury models while reducing common dosing, solubility, and endpoint errors.
-
Structure-Guided Proteomimetics Target SARS-CoV-2 Entry
2026-08-29
The reference study converts two human ACE2 recognition elements into constrained proteomimetics that target the shallow SARS-CoV-2 Spike receptor-binding domain interface. Its lead construct, compound 28, selectively bound the RBD, disrupted RBD–ACE2 binding, inhibited pseudovirus entry, and showed stability and permeability characteristics compatible with further investigation of intranasal antiviral delivery.
-
TLS–TRAF2 Signaling in ESCC
2026-08-28
Using clinical, transcriptomic, single-cell, and in vitro evidence, Zheng et al. identify tertiary lymphoid structures as a favorable prognostic feature in treatment-naïve esophageal squamous cell carcinoma and connect tumor-infiltrating B-cell activity to IRF4. The study proposes that CD40 and STING compete for TRAF2, linking non-canonical NF-κB signaling with STING ubiquitination and phosphorylation in a testable TLS-centered mechanism.
-
HyperPFU™ high-fidelity DNA polymerase Guide
2026-08-28
HyperPFU™ high-fidelity DNA polymerase is intended for accurate amplification of long, GC-rich, inhibitor-affected, or otherwise difficult DNA templates. It is suitable for blunt-ended products used in cloning and sequencing, but should not be selected for workflows that require 3′-A overhangs or preformed sticky ends.
-
G007-LK: Tankyrase 1/2 Inhibitor Workflows
2026-08-27
G007-LK turns tankyrase biology into a practical workflow for measuring Wnt/β-catenin pathway inhibition, β-catenin degradation induction, and tumor-cell growth phenotypes. Its value is greatest when reporter, protein, and long-term proliferation assays are combined rather than interpreted from viability data alone.
-
HyperPFU™ high-fidelity DNA polymerase Guide
2026-08-27
HyperPFU™ high-fidelity DNA polymerase is intended for accurate amplification of long, GC-rich, inhibitor-affected, or otherwise difficult DNA templates. It is suitable for blunt-ended cloning and sequencing workflows, but not for protocols that require 3′-A overhangs or preformed sticky ends.
-
HOBt for Peptide and Medicinal Chemistry Workflows
2026-08-26
HOBt supports high-fidelity amide bond formation when stereochemical control and mild activation are important. This practical guide connects peptide synthesis with the modular medicinal-chemistry workflow used to develop indazole- and indole-based glucagon receptor antagonists.
-
Mifepristone (RU486): Receptor-Aware Assays
2026-08-26
Mifepristone (RU486) is more than a progesterone receptor antagonist: it is a valuable perturbation tool for dissecting hormone-dependent phenotypes. This guide connects oncology and reproductive assays with tissue-specific nuclear receptor biology and practical controls.
-
BAF53a, EMT, and Glioma Prognosis
2026-08-25
Meng et al. identify BAF53a as a prognostic biomarker associated with overall and progression-free survival in glioma and show that altering BAF53a levels changes glioma-cell proliferation, motility, invasion, and EMT-associated marker expression. The study provides a useful mechanistic hypothesis linking a chromatin-remodeling complex subunit with aggressive glioma behavior, while its retrospective cohort and single-cell-line experiments indicate that independent validation is still required.